Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 2/2015

01-06-2015 | Original Research

Epidemiology and Risk Factors for Exocrine Pancreatic Cancer in a Northern African Population

Authors: Feriel Sellam, Noria Harir, Méghit B. Khaled, Nesrine M. Mrabent, Rachida Salah, Mustapha Diaf

Published in: Journal of Gastrointestinal Cancer | Issue 2/2015

Login to get access

Abstract

Background

The etiology of pancreatic cancer remains largely unknown. Although epidemiological studies have reported that many environmental factors may contribute to the development of pancreatic cancer, only age and cigarette smoking have been established as consistent risk factors for the disease.

Objective

Studying the biological clinical and histological features of patients with pancreatic cancer in order to assess the possible risk factors for pancreatic cancer in a North African population.

Methods

An epidemiological retrospective descriptive study has been performed at the level of surgery department of the university hospital of Sidi bel Abbes region, western Algeria, from 2007 to 2013.

Results

A total of 87 patients were diagnosed with cancer of the pancreas (55 males and 32 females) with a mean age of 63.1 years, ranging from 16 to 96 years old, and a sex ratio of 1.71. In 92 % of cases, pancreatic tumors were located at the head of the pancreas; the most predominant histological type was the adenocarcinoma; cigarette smokers represented the rate of 24.3 % and alcoholics 13.5 %. The most recorded disease among patients medical history was diabetes mellitus (25.28 %). About 35.63 % was the prominent rate of patients who underwent cholecystectomy and was diagnosed with pancreatic cancer after an average duration of 5.23 years. Our patients were mostly diagnosed with cancer at M1 and T3 stages.

Conclusion

According to our results, cholecystectomy could possibly be a risk factor for pancreatic cancer in Algerian population
Literature
1.
go back to reference Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Murray T, et al. Cancer statistics. Ca: Cancer J Clin. 2008;58:71–96. Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Murray T, et al. Cancer statistics. Ca: Cancer J Clin. 2008;58:71–96.
2.
go back to reference American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014.
3.
go back to reference Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir. 2004;59:99–111.PubMed Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir. 2004;59:99–111.PubMed
5.
go back to reference Rivard N, Guan D, Maouyo D, Grondin G, Berube FL, Morisset J. Endogenous cholecystokinin release responsible for pancreatic growth observed following pancreatic juice diversion. Endocrinology. 1991;129:2867–74.CrossRefPubMed Rivard N, Guan D, Maouyo D, Grondin G, Berube FL, Morisset J. Endogenous cholecystokinin release responsible for pancreatic growth observed following pancreatic juice diversion. Endocrinology. 1991;129:2867–74.CrossRefPubMed
6.
go back to reference Marx M, Gomez G, Lonovics J, Thompson JC. Cholecystokinin. In: Greeley Jr GH, Rayford PL, Townsend Jr CM, Thompson JC, editors. Gastrointestinal endocrinology. New York: McGraw-Hilln; 1987. p. 213–22. Marx M, Gomez G, Lonovics J, Thompson JC. Cholecystokinin. In: Greeley Jr GH, Rayford PL, Townsend Jr CM, Thompson JC, editors. Gastrointestinal endocrinology. New York: McGraw-Hilln; 1987. p. 213–22.
7.
go back to reference Hyvarinen H, Partanen S. Association of cholecystectomy with abdominal cancers. Hepatogastroenterology. 1987;34:280–4.PubMed Hyvarinen H, Partanen S. Association of cholecystectomy with abdominal cancers. Hepatogastroenterology. 1987;34:280–4.PubMed
8.
go back to reference Smith JP, Salomon TE, Bagheri S, Kramer S. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. Dig Dis Sci. 1990;35:1377–84.CrossRefPubMed Smith JP, Salomon TE, Bagheri S, Kramer S. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. Dig Dis Sci. 1990;35:1377–84.CrossRefPubMed
9.
go back to reference Schiffman SC, Chu KC, Park J, et al. Is prior cholecystectomy associated with decreased survival in patients with resectable pancreatic adenocarcinoma following pancreaticoduodenectomy. Am J Surg. 2011;201:519–24.CrossRefPubMed Schiffman SC, Chu KC, Park J, et al. Is prior cholecystectomy associated with decreased survival in patients with resectable pancreatic adenocarcinoma following pancreaticoduodenectomy. Am J Surg. 2011;201:519–24.CrossRefPubMed
12.
go back to reference Ghadimi BM, Horstmann O, Jacobsen K, et al. Delay of diagnosis in pancreatic cancer due to suspected symptomatic cholelithiasis. Scand J Gastroenterol. 2002;37:1437–9.CrossRefPubMed Ghadimi BM, Horstmann O, Jacobsen K, et al. Delay of diagnosis in pancreatic cancer due to suspected symptomatic cholelithiasis. Scand J Gastroenterol. 2002;37:1437–9.CrossRefPubMed
13.
go back to reference Gray SH, Hawn MT, Kilgore ML, Yun H, Christein JD. Does cholecystectomy prior to the diagnosis of pancreatic cancer affect outcome? Am Surg. 2008;74(7):602–6 (5).PubMed Gray SH, Hawn MT, Kilgore ML, Yun H, Christein JD. Does cholecystectomy prior to the diagnosis of pancreatic cancer affect outcome? Am Surg. 2008;74(7):602–6 (5).PubMed
14.
go back to reference Manousos O, Papadimitriou C, Trichopoulos D. Polychronopoulou A, Koutselinis A, Zavitsanos X. Epidemiologic characteristics and trace elements in pancreatic cancer in Greece. Cancer Detect Prev. 1981;4:439–42.PubMed Manousos O, Papadimitriou C, Trichopoulos D. Polychronopoulou A, Koutselinis A, Zavitsanos X. Epidemiologic characteristics and trace elements in pancreatic cancer in Greece. Cancer Detect Prev. 1981;4:439–42.PubMed
15.
go back to reference GuIIo L, Pezzilli R, Morselli-Labate AM. Risk of pancreatic cancer associated with cholelithiasis, cholecystectomy, or gastrectomy. Dig Dis Sci. 1996;41:1065–8.CrossRef GuIIo L, Pezzilli R, Morselli-Labate AM. Risk of pancreatic cancer associated with cholelithiasis, cholecystectomy, or gastrectomy. Dig Dis Sci. 1996;41:1065–8.CrossRef
16.
go back to reference Kalapothaki V, Tzonou A, Hsieh C, Toupadaki N, Karakatsani A, Trichopoulos D. Tobacco, ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as a risk factors for pancreatic carcinoma. Cancer Causes Control. 1993;4:375–82.CrossRefPubMed Kalapothaki V, Tzonou A, Hsieh C, Toupadaki N, Karakatsani A, Trichopoulos D. Tobacco, ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as a risk factors for pancreatic carcinoma. Cancer Causes Control. 1993;4:375–82.CrossRefPubMed
17.
go back to reference Marieb EN. Human Anatomy and Physiology: 4th ed. Menlo Park; 1998. Marieb EN. Human Anatomy and Physiology: 4th ed. Menlo Park; 1998.
18.
go back to reference Peeters TL, Vantrappen G, Janssens J. Bile acid output and the interdigestive migrating motor complex in normals and in cholecystectomy patients. Gastroenterology. 1980;79(4):678–81.PubMed Peeters TL, Vantrappen G, Janssens J. Bile acid output and the interdigestive migrating motor complex in normals and in cholecystectomy patients. Gastroenterology. 1980;79(4):678–81.PubMed
19.
go back to reference Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586–94.CrossRefPubMed Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586–94.CrossRefPubMed
20.
go back to reference Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.CrossRefPubMed Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.CrossRefPubMed
21.
go back to reference Ferrone CR, Brennan MF, Gonen M, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008;12:701–6.CrossRefPubMed Ferrone CR, Brennan MF, Gonen M, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008;12:701–6.CrossRefPubMed
22.
go back to reference Luman W, Williams AJ, Pryde A, Smith GD, Nixon SJ, Heading RC, et al. Influence of cholecystectomy on sphincter of Oddi motility. Gut. 1997;41:371–4.CrossRefPubMedCentralPubMed Luman W, Williams AJ, Pryde A, Smith GD, Nixon SJ, Heading RC, et al. Influence of cholecystectomy on sphincter of Oddi motility. Gut. 1997;41:371–4.CrossRefPubMedCentralPubMed
24.
go back to reference Miller LJ, Holicky EL, Ulrich CD, Wieben ED. Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity. Gastroenterology. 1995;109:1375–80.CrossRefPubMed Miller LJ, Holicky EL, Ulrich CD, Wieben ED. Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity. Gastroenterology. 1995;109:1375–80.CrossRefPubMed
25.
go back to reference Ding X, Lu CY, Mei Y, Liu CA, Shi YJ. Correlation between gene expression of CCK-A receptor and emptying dysfunction of the gallbladder in patients with gallstones and diabetes mellitus. HepatobiliaryPancreat. Dis Int. 2005;4:295–8. Ding X, Lu CY, Mei Y, Liu CA, Shi YJ. Correlation between gene expression of CCK-A receptor and emptying dysfunction of the gallbladder in patients with gallstones and diabetes mellitus. HepatobiliaryPancreat. Dis Int. 2005;4:295–8.
26.
go back to reference Weinberg DS, Ruggeri B, Barber IMT, Biswas S, Miknyocki IS, Scott A. Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma. Am Soc Clin Invest. 1997;100(3):597–603.CrossRef Weinberg DS, Ruggeri B, Barber IMT, Biswas S, Miknyocki IS, Scott A. Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma. Am Soc Clin Invest. 1997;100(3):597–603.CrossRef
Metadata
Title
Epidemiology and Risk Factors for Exocrine Pancreatic Cancer in a Northern African Population
Authors
Feriel Sellam
Noria Harir
Méghit B. Khaled
Nesrine M. Mrabent
Rachida Salah
Mustapha Diaf
Publication date
01-06-2015
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 2/2015
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-015-9693-4

Other articles of this Issue 2/2015

Journal of Gastrointestinal Cancer 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.